Arrowhead Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 13 analysts polled by S&P Global, Arrowhead Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $110. The average 1-year stock price forecast is 59.91% higher than the current stock price, while the lowest is $100 (+45.37%) and the highest is $126 (+83.17%).

Price Target: $110 (+59.91%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$100	$110	$106	$126
Change	+45.37%	+59.91%	+54.09%	+83.17%

Analyst Ratings

The average analyst rating for Arrowhead Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	Apr '26	May '26	Jun '26	Jul '26	Aug '26	Sep '26
Strong Buy	7	7	7	8	8	9
Buy	3	4	4	4	4	4
Hold	2	2	2	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	12	13	13	12	12	13

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Patrick Trucchio H.C. Wainwright	H.C. Wainwright	Buy Maintains $120	Buy	Maintains	$120	+74.44%	Sep 21, 2026
Eric Joseph Citi	Citi	Buy Reiterates n/a	Buy	Reiterates	n/a	n/a	Sep 16, 2026
Brian Cheng J.P. Morgan	J.P. Morgan	Buy Reiterates n/a	Buy	Reiterates	n/a	n/a	Sep 16, 2026
Michael Ulz Morgan Stanley	Morgan Stanley	Buy Reiterates $120	Buy	Reiterates	$120	+74.44%	Sep 1, 2026
Luca Issi RBC Capital	RBC Capital	Buy Maintains $100	Buy	Maintains	$100	+45.37%	Aug 31, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

461.20M

from 829.45M

-44.40%

from 829.45M

Revenue Next Year

339.94M

from 461.20M

-26.29%

from 461.20M

EPS This Year

-3.54

from -0.01

EPS Next Year

-4.80

from -3.54

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Sep 30, 2021	Sep 30, 2022	Sep 30, 2023	Sep 30, 2024	Sep 30, 2025	Sep 30, 2026
Revenue	138.29M	243.23M	240.74M	3.55M	829.45M	461.20M
Revenue Growth	57.16%	75.89%	-1.03%	-98.53%	23,258.15%	-44.40%
Gross Profit	138.29M	243.23M	240.74M	3.55M	829.45M	460.85M
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	99.93%
Operating Income	-149.04M	-178.51M	-205.00M	-601.08M	98.35M	-477.36M
Net Income	-140.85M	-176.06M	-205.28M	-599.49M	-1.63M	-518.49M
EPS	-	-	-	-	-0.01	-3.54
Free Cash Flow	-	-	-	-	156.89M	-550.20M
No. Analysts	-	-	-	-	-	14

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	590.7M
Avg	461.2M
Low	417.5M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	-28.8%
Avg	-44.4%
Low	-49.7%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-2.45
Avg	-3.54
Low	-5.14

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-